NCT06140108

Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity

Comparing the Effects of Empagliflozin and Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: SINA Health Education and Welfare Trust · Academic / Other
• Sex: Female
• Age: 15 Years – 49 Years
• Healthy volunteers: Not accepted

Summary

this is open labelled randomize control trial among women with PCOS. PCOS, an endocrine condition, affects 5%-15% of premenopausal women. PCOS is characterized by atypical menstruation, ovulation difficulties, hyperandrogenemia, insulin resistance, and other metabolic abnormalities. Metformin is now an option for PCOS. The clinical reactions to metformin are limited and varied. Novel SGLT2 inhibitors treat type 2 diabetes with weight loss, insulin resistance reduction, and cardiovascular benefits. There is little evidence on SGLT2 inhibitor effectiveness in PCOS patients.

Conditions

• Polycystic Ovary Syndrome
• Weight Gain
• HbA1c

Interventions

Type	Name	Description
DRUG	Empagliflozin 10 MG	Each participant will receive empagliflozin 10mg daily for 6 months.
DRUG	MetFORMIN 500 Mg Oral Tablet	Each participant will receive metformin 1000mg daily for 6 months.

Timeline

• Start date: 2023-12-15
• Primary completion: 2024-05-30
• Completion: 2024-06-30
• First posted: 2023-11-18
• Last updated: 2025-05-14

Locations

1 site across 1 country: Pakistan